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across every stage, all of which are fully transparent, provides a unique combination 
of broadness, resilience and inclusiveness making it an ideal decision making tool.
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Objectives: Many aspects of QALY measurement in children are not yet fully 
developed. This study is aimed at contextualizing the mapping methodology 
in a field not yet covered: paediatric asthma. The objective is to derive utility 
values from non-preference-based questionnaires, the estimated utility values 
will be useful for QALY assessment by means of: i) evaluation of a linear map-
ping between the generic preference-based EQ-5D-3L (self- and proxy-versions) 
and the condition-specific non-preference-based Paediatric Asthma Quality of 
Life Questionnaire (PAQLQ) and Paediatric Asthma Caregiver’s Quality of Life 
Questionnaire (PACQLQ), respectively; ii) assessment of the capability of map-
ping to discriminate for disease severity. MethOds: Either PAQLQ or PACQLQ and 
EQ-5D-3L will be administrated to 170 asthma children (7-17 years of age) during 
a 24-month multicenter randomized placebo-controlled trial of allergen specific 
sublingual immunotherapy coded EudraCT No. 2012-005678-76/FARM94793N at 
baseline, month 12, and month 24 visits. Level of severity will be assessed using 
the Asthma Control Test (ACT) and the Childhood-ACT (C-ACT) questionnaires. 
The possibility of a linear mapping will be evaluated through a Tobit model, where 
either PAQLQ/PACQLQ will be tested as predictors of EQ-5D-3L answers. Capability 
of mapping to be sensible in changes of disease severity will be measured 
through a Pearson’s correlation between changes in estimated EQ-5D-3L scores 
and changes in ACT and C-ACT answers. Results: Linear mapping, if feasible, 
applies the statistical relationship between either PAQLQ or PACQLQ and EQ-5D-3L, 
being PAQLQ/PACQLQ answers predictors of EQ-5D-3L score. EQ-5D-3L and PAQLQ/
PACQLQ, as well as EQ-5D-3L built on PAQLQ/PACQLQ answers by applying the 
linear mapping is expected to discriminate for both patients’ level and changes 
in disease severity. cOnclusiOns: This study seeks to inform policy makers in 
their choice of the source of utility values and their discrimination across severity 
groups and responsiveness in asthma children.
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Objectives: Guidelines for economic evaluation from ISPOR and NICE recom-
mend the use of mean values rather than medians, but do not offer guidance for 
situations when mean values are not available. This study evaluated the impact 
of different methods of estimating means from medians, within the context of 
estimating treatment duration for drugs used to treat mCRC. MethOds: Clinical 
trials and prescribing information for drugs used to treat mCRC were reviewed 
for information on the mean, median, and range of treatment cycles. Various 
approaches were used to estimate mean values, including direct use of the median, 
a published equation considering the median and range, confidence intervals and 
interquartile range, and the use of distributions commonly used in survival analy-
sis. Where possible, the estimated means were compared with reported means 
from clinical trials. Results: Very few studies reported both median and mean 
treatment duration; direct use of the median under-predicted the mean by 23-39% 
and the published equation over-predicted the mean by 19-28%. Simple assump-
tions about the distribution of treatment durations performed best, predicting the 
reported mean within ±12%. The use of progression-free survival as a proxy for 
treatment duration over-predicted treatment duration by 5-38%, although esti-
mates were improved by accounting for early discontinuation. cOnclusiOns: 
By only considering the 50th percentile, the median may not provide an accurate 
representation of the outcomes in a population. It is important that researchers 
and budget-holders are aware of the limitations in the use of medians, and that 
they consider multiple estimation methods to estimate mean values for economic 
analyses.
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Objectives: Prostate cancer (PCa) incidence has been steadily increasing over the 
last twenty years, resulting in Ireland having the highest incidence rate in Europe 
in 2008. The main driver of this is wide-spread use of prostate specific antigen 
(PSA) testing in primary care as an ad-hoc detection mechanism. The objective of 
this research was to undertake a cost-effectiveness analysis of organised screening 
using PSA testing in Ireland. MethOds: Using a Bayesian Multi-Parameter Evidence 
Synthesis (MPES) framework, non-cost parameters were synthesised, informed by 
incidence, mortality and clinical data from the National Cancer Registry Ireland 
for men diagnosed with PCa in 2009. The MPES framework estimates unobserved 
parameters using available evidence and so facilitates analysis of interventions 
where observational data is limited. Average costs were estimated using project-
specific survey costs, Irish hospital costs (HSE Casemix) and costs published in the 
literature. Effectiveness of PSA testing was sourced from the literature. Utility scores 
were collected from 2,500 PCa survivors. The cost-effectiveness analysis employed 
a cohort, semi-Markov model following men from age 30 to death. A range of PSA 
screening strategies were compared with no PSA testing and an extensive series of 
increases with higher test costs, smaller subgroup and smaller incremental effects 
due to the treatment change. cOnclusiOns: The data collection of costs, survival 
and quality of life of PMAs should be restricted to the subgroup for whom treat-
ment changes. Therefore, cost-effectiveness analyses of PMAs should start with 
identifying that subgroup. Once the size of the subgroup, the cost-effectiveness 
of the treatment change and the test costs are known, the full cost-effectiveness 
can be easily calculated. The described function can also be used to assess the 
potential cost-effectiveness of future PMAs. If a PMA causes a treatment change 
in a small subgroup, the PMA can only be cost-effective with low test costs or 
large incremental effects.
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Objectives: Health economic evaluations (HEEs) of vaccines are commonly con-
sidered during immunization introduction decision-making processes in most 
industrialized countries. Despite the availability of guidelines advocating more 
standardization for such HEEs, there are still several infection/immunization-spe-
cific particularities that are debated in the scientific community. An international 
expert-workshop was convened to identify good practices for (i) how to conduct 
HEEs of vaccines and (ii) how to consider results of HEE in vaccine introduction 
decision-making. MethOds: A systematic literature search was conducted to 
identify prevailing opinions and remaining issues of HEE in vaccination. Twenty-
two experts in the field of health economics and immunization decision-making 
were invited to a workshop and were asked to answer a survey-questionnaire 
based on the systematic literature search beforehand to inform the prepara-
tion of group work sessions (GWS). In GWS, issues focusing on ‘mathematical 
modeling’, ‘health economics’, and ‘decision-making’ were discussed and sum-
marized. Results: The GWS (based on systematic literature search) included 
topics such as cost-components, quality of life (QoL), discounting, and perspec-
tives leading to suggestions such as including caregiver QoL impact and applying 
decreasing time-related discount rates. Since vaccination often causes indirect 
effects, the use of dynamic models is required and exceptions should be justi-
fied. In order to facilitate transparent decision-making, the results of HEE should 
present parameter and methodological uncertainty as well as cumulative and 
time-specific figures. The majority of countries in Europe use results from HEEs 
in an informal judgment-process without willingness to pay (WTP) threshold. The 
expert-group emphasized that transparency should be maximized in decision-
making process. cOnclusiOns: The deliberations led to suggestions on several 
HEE issues. However, vaccines not always need to be considered differently in HEE 
since other interventions might share similar characteristics. Transparency in the 
conduct and presentation of HEE, and subsequent decision-making is essential, 
especially in the absence of explicit WTP thresholds.
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Objectives: To apply in practise an MCDA framework for the value assessment of 
a set of therapeutic options in regards to an oncology indication through an HTA 
simulation exercise. MethOds: Using MCDA principles, past research outcomes 
and the clinical and economic literature, a disease specific value tree was con-
structed incorporating the values concerned as criteria. The alternative options 
were scored against the criteria through the development of value functions, 
weights were assigned to the criteria using a swing method, scores and weights 
were aggregated using a linear additive model, and sensitivity analysis of the results 
was conducted. All the stages were informed by extensive stakeholder engage-
ment through their participation at a decision conference workshop. Results: 
Value parameters considered included burden of illness, therapeutic, safety, inno-
vation and socioeconomic criteria. Overall value scores were produced reflecting 
the performance of the options against the criteria while considering their relative 
importance. Hypothetical payer’s resource allocation decisions on the coverage of 
the options were made on “value for money” grounds through the use of “cost-per-
unit of value” that was derived by incorporating purchasing costs. cOnclusiOns: 
MCDA possesses the prerequisites of a value based assessment methodological 
framework. The multiplicity of criteria that can be incorporated to assess value, 
the weights that can be applied to the criteria, and the stakeholders’ involvement 
